Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program
Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.
Pharma & Biotech
Features & Analysis
Why Indivior’s Delaware redomiciliation matters more than a corporate address change
Find out how Indivior’s move to the United States reshapes governance, regulation, and investor perception in addiction treatment biotech.
Pharma & Biotech
Indivior’s SUBLOCADE shows stronger outcomes in high-frequency fentanyl users: What this changes for opioid use disorder treatment in 2026
Indivior's new data shows SUBLOCADE 300 mg may improve outcomes in fentanyl users with OUD. Find out what this means for future treatment.